Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04261907
Recruitment Status : Terminated (There were no more subjects enrolled.)
First Posted : February 10, 2020
Last Update Posted : April 4, 2022
Ascletis Pharmaceuticals Co., Ltd.
Information provided by (Responsible Party):
First Affiliated Hospital of Zhejiang University

Brief Summary:
Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.

Condition or disease Intervention/treatment Phase
2019-nCoV Drug: ASC09/ritonavir group Drug: lopinavir/ritonavir group Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection
Actual Study Start Date : February 11, 2020
Actual Primary Completion Date : April 13, 2020
Actual Study Completion Date : April 13, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ASC09/ritonavir group
ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
Drug: ASC09/ritonavir group
ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment

Active Comparator: lopinavir/ritonavir group
Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
Drug: lopinavir/ritonavir group
Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment

Primary Outcome Measures :
  1. The incidence of composite adverse outcome [ Time Frame: 14 days ]
    Defined as(one of them) SPO2≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300mmHg or RR ≥ 30 breaths per.

Secondary Outcome Measures :
  1. Time to recovery [ Time Frame: 14 days ]
    Clinical recovery was defined as( one of them): sustained (48 hours) alleviation of illness based on symptom scores (fever, cough,diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline ≥3%, respiratory rate ≥ 24 breaths per min without supplemental oxygen). Or undectable viral RNA.

  2. Rate of no fever [ Time Frame: 14 days ]
  3. Rate of no cough [ Time Frame: 14 days ]
  4. Rate of no dyspnea [ Time Frame: 14 days ]
  5. Rate of no requring supplemental oxygen [ Time Frame: 14 days ]
  6. Rate of undectable viral RNA [ Time Frame: 14 days ]
  7. Rate of mechanical ventilation [ Time Frame: 14 days ]
  8. Rate of ICU admission [ Time Frame: 14 days ]
  9. Time and rate of laboratory indicators related to disease improvement to return to normal [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Aged between 18 and 75 years, extremes included, male or female
  • 2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia, according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"
  • 3. Hospitalised with a new onset respiratory illness (≤7 days since illness onset)
  • 4. No family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose
  • 5. Must agree not to enroll in another study of an investigational agent prior to completion of Day 30 of study
  • 6. Informed Consent Form (ICF) signed voluntarily

Exclusion Criteria:

  • 1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress, RR ≥ 30 times / min, or SaO2 / SpO2 ≤ 93% in resting state, or arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg (1mmHg = 0.133kpa)
  • 2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory failure and mechanical ventilation required, or shock, or combined with other organ failure required ICU monitoring treatment
  • 3. Severe liver disease (e.g. Child Pugh score ≥ C, AST > 5 times upper limit)
  • 4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets
  • 5. Patients with definite contraindications in the label of ritonavir
  • 6. Positive serum pregnancy test result for women with childbearing potential at screening
  • 7. Using HIV protease inhibitor drugs
  • 8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be transferred to another hospital during the study period, patient with multiple basic diseases, etc.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04261907

Layout table for location information
China, Zhejiang Province, P.R. China
The first affiliated hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang Province, P.R. China, China, 310003
Sponsors and Collaborators
First Affiliated Hospital of Zhejiang University
Ascletis Pharmaceuticals Co., Ltd.
Layout table for investigator information
Principal Investigator: Yunqing Qiu, Master First Affiliated Hospital of Zhejiang University
Layout table for additonal information
Responsible Party: First Affiliated Hospital of Zhejiang University Identifier: NCT04261907    
Other Study ID Numbers: ASC09F-CTP-ZY-01
First Posted: February 10, 2020    Key Record Dates
Last Update Posted: April 4, 2022
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Pneumonia, Viral
Lung Diseases
Respiratory Tract Diseases
HIV Protease Inhibitors
Viral Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors